Skip to main content

Question for Department of Health

UIN 203015, tabled on 30 June 2014

To ask the Secretary of State for Health, if he will request that the National Institute for Health and Care Excellence examines the use of Sativex or other appropriate cannabis derivatives for treatment of spasticity due to stroke.

Answered on

7 July 2014

Sativex (nabiximols) does not have a marketing authorisation for use in the treatment of spasticity due to stroke and there are no current plans to ask the National Institute for Health and Care Excellence to issue guidance on the drug or other cannabis derivatives for this indication.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.